On September, 26th Azhar Giniyat, Minister of Healthcare in Kazakhstan, held a meeting with Maria Shipuleva, Country Director, AstraZeneca Kazakhstan. During the meeting parties signed localization project roadmap, aimed at contract production of AstraZeneca’s original medicines in Kazakhstan.
The signing of the localization project roadmap is a major step towards the fulfillment of instructions assigned by the President of Kazakhstan K.K.Tokayev on bringing the share of domestically produced drugs to 50% in the domestic market. It also meets the intentions of the country's leadership to improve the investment climate and develop bilateral strategic relations.
Azhar Giniyat, Minister of Healthcare of the Republic of Kazakhstan: «The signing of the roadmap draft is an important event for the development of the pharmaceutical industry in Kazakhstan. Thanks to this project, citizens of Kazakhstan will receive the access to AstraZeneca’s innovative medicines. We also expect the project to contribute to increasing the scientific and human resources potential for the pharmaceutical and medical industry of Kazakhstan».
In addition to localization of AstraZeneca’s medicines, the roadmap will be aimed at building strategic partnership, scientific and human potential for the pharmaceutical and medical industry in Kazakhstan.
Leo Docherty, Leo Docherty, The Minister for Europe of the United Kingdom of Great Britain and Northern Ireland: «I welcome the significant investment that AstraZeneca is making in Kazakhstan, to support development and innovation in the country’s drugs market. I’m proud of the role UK companies and expertise can and have played in helping Kazakhstan fulfil its economic potential».
AstraZeneca plays a significant role in the development of the pharmaceutical industry in Kazakhstan. The company is sommittted to a long-term partnership with both the government and the medical community. The signing of the roadmap confirms the company's intention to strengthen local manufacturing capabilities and create a favorable environment for the production of innovative medicines.
Daulet Saktaganov, project manager of "National Company "Kazakhs Invest": Undoubtedly, the implementation of investment projects in the field of pharmaceuticals remains one of the most important activities of the National Company "Kazakh Invest". Partnership with such a giant of pharmaceutical industry as AstraZeneca is totally in line with the industry development strategy supported by the President of the Republic K.K.Tokayev. It is a signal to all major pharmaceutical companies that Kazakhstan is a favorable place for the implementation of such investment projects.
Mariya Shipuleva, Country Director, «AstraZeneca» Kazakhstan: «Localization of patented molecules is an important step that we need to take to create a strong and sustainable pharmaceutical sector in Kazakhstan. The signing of the roadmap is a significant event for us. It will allow us to plot the trajectory of further actions to develop the local production of AstraZeneca’s medicines and ensure their access for patients in Kazakhstan».
About «AstraZeneca»
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com.
